Table 2.
Outcomes of studies of radioembolization in patients with liver metastases from neuroendocrine tumours
| Study | Patients, n | Device used | Toxicity | Radiological response (RECIST 1.0) | Survival times and rates |
|---|---|---|---|---|---|
| Rhee et al.22 | 42 | Yttrium-90 (glass) | Grade III/IV (14%) | 54% | Median: 22 months |
| Yttrium-90 (resin) | 50% | Median: 28 months | |||
| Kennedy et al.18 | 148 | Yttrium-90 (resin) | 33% (grade III), fatigue (6.5%) | 63% | Median: 70 months |
| King et al.19 | 58 | Yttrium-90 (resin) plus 5-FU | Radiation gastritis (2 patients), duodenal ulcer (1 patient) | 39% | Median: 36 months 1-, 2- and 3-year survival: 86%, 58% and 47%, respectively |
| Saxena et al.23 | 48 | Yttrium-90 (resin) | 0.5% (grade III) 1 patient (biliary obstruction) | 54% | Median: 35 months 1-, 2- and 3-year survival: 87%, 62% and 42%, respectively |
| Cao et al.17 | 58 | Yttrium-90 (resin) plus 5-FU | Not reported | 39.2% | Median: 36 months |
| Paprottka et al.21 | 42 | Yttrium-90 (resin) | 0% grade III | 22.5% | Median: 95% at 16.2 months |
| Memon et al.20 | 40 | Yttrium-90 (glass) | Fatigue (63%, all grades), nausea/vomiting (40%, all grades), grade III, IV (bilirubin, 8%; albumin, 2%; lymphocyte, 38%) | WHO: 64.0%; EASL: 71.4% | Median: 34.4 months 1-, 2- and 3-year survival: 72.5%, 62.5%, 45.0%, respectively |
5-FU, 5-fluorouracil; EASL, European Association for the Study of the Liver; WHO, World Health Organization.